{"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"41"}],"units":"Participants"}],"groups":[{"description":"Patients rcvd oral erlotinib 150 mg/day. Cohort 1 pts would have at least 28 days and no more than 42 days of therapy in advance of definitive therapy (surgery or chemoradiation). Two potential dose reductions were prescribed to 100 and 50 mg/day.","id":"BG000","title":"Erlotinib-Cohort 1"},{"description":"Patients rcvd oral erlotinib 150 mg/day. Cohort 2 pts continued on therapy (28 days per cycle) until disease progression, unacceptable toxicity or withdrawal of consent. Two potential dose reductions were prescribed to 100 and 50 mg/day.","id":"BG001","title":"Erlotinib-Cohort 2"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"58","upperLimit":"94","value":"75"},{"groupId":"BG001","lowerLimit":"49","upperLimit":"86","value":"71.5"},{"groupId":"BG002","lowerLimit":"49","upperLimit":"94","value":"73"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"41"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"41"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"The analysis population is comprised of all enrolled patients."}